Repeated clinical malaria episodes are associated with modification of the immune system in children.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
13 03 2019
Historique:
received: 19 11 2018
accepted: 18 02 2019
entrez: 14 3 2019
pubmed: 14 3 2019
medline: 14 11 2019
Statut: epublish

Résumé

There are over 200 million reported cases of malaria each year, and most children living in endemic areas will experience multiple episodes of clinical disease before puberty. We set out to understand how frequent clinical malaria, which elicits a strong inflammatory response, affects the immune system and whether these modifications are observable in the absence of detectable parasitaemia. We used a multi-dimensional approach comprising whole blood transcriptomic, cellular and plasma cytokine analyses on a cohort of children living with endemic malaria, but uninfected at sampling, who had been under active surveillance for malaria for 8 years. Children were categorised into two groups depending on the cumulative number of episodes experienced: high (≥ 8) or low (< 5). We observe that multiple episodes of malaria are associated with modification of the immune system. Children who had experienced a large number of episodes demonstrated upregulation of interferon-inducible genes, a clear increase in circulating levels of the immunoregulatory cytokine IL-10 and enhanced activation of neutrophils, B cells and CD8 Transcriptomic analysis together with cytokine and immune cell profiling of peripheral blood can robustly detect immune differences between children with different numbers of prior malaria episodes. Multiple episodes of malaria are associated with modification of the immune system in children. Such immune modifications may have implications for the initiation of subsequent immune responses and the induction of vaccine-mediated protection.

Sections du résumé

BACKGROUND
There are over 200 million reported cases of malaria each year, and most children living in endemic areas will experience multiple episodes of clinical disease before puberty. We set out to understand how frequent clinical malaria, which elicits a strong inflammatory response, affects the immune system and whether these modifications are observable in the absence of detectable parasitaemia.
METHODS
We used a multi-dimensional approach comprising whole blood transcriptomic, cellular and plasma cytokine analyses on a cohort of children living with endemic malaria, but uninfected at sampling, who had been under active surveillance for malaria for 8 years. Children were categorised into two groups depending on the cumulative number of episodes experienced: high (≥ 8) or low (< 5).
RESULTS
We observe that multiple episodes of malaria are associated with modification of the immune system. Children who had experienced a large number of episodes demonstrated upregulation of interferon-inducible genes, a clear increase in circulating levels of the immunoregulatory cytokine IL-10 and enhanced activation of neutrophils, B cells and CD8
CONCLUSION
Transcriptomic analysis together with cytokine and immune cell profiling of peripheral blood can robustly detect immune differences between children with different numbers of prior malaria episodes. Multiple episodes of malaria are associated with modification of the immune system in children. Such immune modifications may have implications for the initiation of subsequent immune responses and the induction of vaccine-mediated protection.

Identifiants

pubmed: 30862316
doi: 10.1186/s12916-019-1292-y
pii: 10.1186/s12916-019-1292-y
pmc: PMC6415347
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

60

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M003906/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P020321/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT 206194
Pays : United Kingdom

Références

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):E511-20
pubmed: 24474800
PLoS Pathog. 2014 Jan;10(1):e1003864
pubmed: 24415936
Nat Med. 2017 Oct;23(10):1220-1225
pubmed: 28892065
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Rev Immunol. 2014 Apr;14(4):271-80
pubmed: 24662387
J Immunol. 2013 Feb 1;190(3):1038-47
pubmed: 23264654
Science. 2014 Jun 27;344(6191):1492-6
pubmed: 24970081
Scand J Immunol. 1999 Dec;50(6):642-50
pubmed: 10607313
PLoS One. 2012;7(10):e48126
pubmed: 23144737
Indian J Med Res. 1997 Aug;106:109-19
pubmed: 9291681
PLoS Pathog. 2016 Oct 12;12(10):e1005945
pubmed: 27732671
Infect Immun. 2004 Oct;72(10):5630-7
pubmed: 15385460
Am J Trop Med Hyg. 2008 Aug;79(2):185-91
pubmed: 18689622
Lancet. 2002 Apr 13;359(9314):1311-2
pubmed: 11965279
Mol Biochem Parasitol. 2001 Dec;118(2):247-51
pubmed: 11738714
Clin Infect Dis. 2013 Jul;57(1):40-7
pubmed: 23487390
Cell Rep. 2013 Dec 12;5(5):1204-13
pubmed: 24316071
N Engl J Med. 2012 Dec 13;367(24):2284-95
pubmed: 23136909
Semin Immunopathol. 2015 May;37(3):221-31
pubmed: 25772948
EMBO Mol Med. 2013 Jul;5(7):984-99
pubmed: 23681698
J Immunol. 2009 Aug 1;183(3):2176-82
pubmed: 19592645
J Immunol. 1994 Aug 1;153(3):1187-94
pubmed: 8027548
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Scand J Immunol. 2004 Feb;59(2):228-30
pubmed: 14871301
J Exp Med. 2013 Jul 29;210(8):1635-46
pubmed: 23835848
Nat Commun. 2013;4:2836
pubmed: 24284865
Immunity. 2011 Aug 26;35(2):194-207
pubmed: 21820332
Infect Immun. 2001 May;69(5):3190-6
pubmed: 11292740
Sci Rep. 2016 May 24;6:26210
pubmed: 27217330
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15401-6
pubmed: 22949644
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
BMC Med. 2016 Sep 22;14(1):143
pubmed: 27660116
Eur J Immunol. 2011 Sep;41(9):2688-98
pubmed: 21674481
Nature. 2017 Oct 26;550(7677):515-518
pubmed: 29019978
Immunity. 2013 Apr 18;38(4):831-44
pubmed: 23601689
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
JCI Insight. 2017 Aug 3;2(15):
pubmed: 28768916
Curr Opin Immunol. 2013 Oct;25(5):571-8
pubmed: 24148234
J Immunol. 2012 Dec 1;189(11):5336-46
pubmed: 23100518
J Infect Dis. 2005 Jun 1;191(11):1932-9
pubmed: 15871128
Immunity. 2008 Jul 18;29(1):150-64
pubmed: 18631455
Nature. 2017 Dec 7;552(7683):101-105
pubmed: 29186116
Trop Med Int Health. 2005 Jun;10(6):530-6
pubmed: 15941415
Nat Immunol. 2008 Jul;9(7):725-32
pubmed: 18563083
BMC Bioinformatics. 2017 Mar 22;18(Suppl 4):117
pubmed: 28361706
Immunity. 2005 Sep;23(3):287-96
pubmed: 16169501
Clin Exp Immunol. 1997 Jul;109(1):84-9
pubmed: 9218829
Infect Immun. 2000 Jul;68(7):3909-15
pubmed: 10858202
Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60
pubmed: 16438676
Arthritis Rheumatol. 2014 Jun;66(6):1583-95
pubmed: 24644022
J Immunol. 2007 Sep 15;179(6):4193-201
pubmed: 17785859
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
J Immunol. 2017 Dec 1;199(11):3781-3788
pubmed: 29079696
F1000Res. 2015 Sep 29;4:919
pubmed: 28883910
PLoS One. 2016 Apr 27;11(4):e0154253
pubmed: 27119555
Sci Transl Med. 2014 Aug 27;6(251):251ra117
pubmed: 25163477
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14509-14
pubmed: 18799734
PLoS Pathog. 2014 Apr 17;10(4):e1004079
pubmed: 24743880
Am J Trop Med Hyg. 2003 Jun;68(6):734-42
pubmed: 12887036
Int J Parasitol. 2012 May 15;42(6):549-55
pubmed: 22549022
J Infect Dis. 1990 Jul;162(1):283-5
pubmed: 2192010
PLoS Comput Biol. 2016 Sep 23;12(9):e1005112
pubmed: 27662185
PLoS Pathog. 2011 Dec;7(12):e1002389
pubmed: 22144890

Auteurs

Yaw Bediako (Y)

Francis Crick Institute, London, UK.

Rhys Adams (R)

Francis Crick Institute, London, UK.

Adam J Reid (AJ)

Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.

John Joseph Valletta (JJ)

University of Exeter, Exeter, UK.

Francis M Ndungu (FM)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

Jan Sodenkamp (J)

Francis Crick Institute, London, UK.
Present Address: Transla TUM, Zentralinstitut für translationale Krebsforschung der Technischen Universität München, Munich, Germany.

Jedidah Mwacharo (J)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

Joyce Mwongeli Ngoi (JM)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Present Address: West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.

Domtila Kimani (D)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

Oscar Kai (O)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

Juliana Wambua (J)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

George Nyangweso (G)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

Etienne P de Villiers (EP)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Mandy Sanders (M)

Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.

Magda Ewa Lotkowska (ME)

Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.

Jing-Wen Lin (JW)

Francis Crick Institute, London, UK.
Present Address: Division of Pediatric Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University and Collaboration Innovation Centre, Chengdu, China.

Sarah Manni (S)

Francis Crick Institute, London, UK.

John W G Addy (JWG)

Francis Crick Institute, London, UK.

Mario Recker (M)

University of Exeter, Exeter, UK.

Chris Newbold (C)

Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Matthew Berriman (M)

Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.

Philip Bejon (P)

KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.

Kevin Marsh (K)

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Jean Langhorne (J)

Francis Crick Institute, London, UK. jean.langhorne@crick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH